ANAda Niezgoda

Ada Niezgoda

*This is an algorithmically generated author record based on publicly available information.

Ada Niezgoda has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global Longitudinal Strain in different forms of exercise-related cardiac remodeling

    by Paweł Kosiorek, Anna Izabela Garbacz, Tomasz Julian Majszyk, Jacek Głuski, Agnieszka Brzozowska, Patrycja Anna Borowiecka, Aleksandra WęGlarz, Ada Niezgoda, Anna Olborska, Bartłomiej Maciej Wrochna, et al.

    Background: Cardiac structure and haemodynamic parameters reflect distinct patterns of adaptation to exercise. Global longitudinal strain (GLS) is an echocardiographic measure of myocardial deformation that may detect subtle changes in systolic function. Aim: This paper aims to analyze changes in GLS associated with different athletic disciplines, training characteristics and acute exercise, and to discuss the clinical interpretation of GLS in physiological versus pathological cardiac remodelling. Material and methods: Literature data on the use of GLS in athletes and in the assessment of exercise-related cardiac remodelling were analyzed. This narrative review included studies published between 2010 and 2025 retrieved from PubMed, Scopus, and Web of Science using combinations of the terms GLS, speckle-tracking echocardiography, strain analysis and athlete’s heart. Results: The reviewed studies demonstrate heterogeneous GLS patterns among athletes and across athletic disciplines. Acute prolonged exercise may produce transient changes in myocardial strain, whereas chronic training is associated with variable adaptations depending on exercise modality and cardiac remodelling. Conclusions: GLS should not be interpreted using a single athlete-specific threshold. Its interpretation should consider athletic discipline, training status, ventricular geometry, loading conditions and the timing of measurement relative to exercise.

  • Open Access

    Does paternal pre-conceptional drinking affects development of autism spectrum disorder, FAS and ADHD in children?

    by Ada Niezgoda, Anna Garbacz, Tomasz Majszyk, Jacek Głuski, Agnieszka Brzozowska, Patrycja Borowiecka, Aleksandra WęGlarz, Paweł Kosiorek, Anna Olborska, Bartłomiej Wrochna, et al.

    The aim of this study was to investigate the association between paternal drinking before conception and the development of autism spectrum disorder (ASD), fetal alcohol syndrome (FAS) and attention deficit hyperactivity disorder (ADHD). Parental alcohol consumption is mentioned as one of the main potential development factors of these disorders. There are already a large number of studies proving a strong link between maternal alcohol consumption during pregnancy and FAS and hypothesis concerning links with ADHD and ASD. Paternal pre-conceptional alcohol consumption impact on fetus neurodevelopment is not so extensively researched and discussed as the case of maternal drinking. However, a number of experimental studies on animals have demonstrated decreased litter size, increased prevalence of low-weight fetuses at birth, risk of malformations and cognitive and behavioral impairment, which include learning and memory deficits, hyperactivity, and poor stress tolerance. Both animal and human studies proved the adverse impact of alcohol on sperm that may cause developmental disorders of offspring. In this study, the existing data on human paternal preconceptual alcohol consumption and its effect on ASD, FAS, ADHD are reviewed.

  • Open Access

    Prenatal Paracetamol Exposure and Offspring ADHD Risk: A Narrative Review of Evidence, Plausibility, and Implications

    by Anna Olborska, Bartłomiej Maciej Wrochna, Agnieszka Brzozowska, Gabriela Stondzik, Anna Izabela Garbacz, Paweł Kosiorek, Agnieszka Radziwonka, Tomasz Julian Majszyk, Jacek Głuski, Patrycja Anna Borowiecka, et al.

    Background: Paracetamol is the most commonly used analgesic and antipyretic during pregnancy. Concurrently, attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition. Recent evidence has raised concerns regarding the potential impact of prenatal paracetamol exposure on offspring ADHD risk. Objective: To examine the current evidence linking prenatal paracetamol exposure to ADHD, evaluate biological plausibility, and assess clinical and public health implications. Methods: This narrative review synthesized findings from prospective cohort studies, case–control studies, and meta-analyses published mostly within the past decade and indexed in PubMed, PMC, Lancet. Results: Several observational cohort studies and meta-analyses report modest associations between prenatal paracetamol exposure and increased risk of ADHD. Meta-analyses and umbrella reviews highlight moderate heterogeneity and substantial vulnerability to residual confounding, particularly confounding by indication and shared familial factors. Importantly, large nationwide cohort studies incorporating sibling-controlled analyses suggest that previously observed relationships may largely reflect genetic, environmental, or maternal health-related confounding rather than causal effects. Conclusion: Recent reviews emphasize that while observed associations warrant a precautionary approach, the available evidence from observational studies cannot establish a causal link between typical prenatal acetaminophen (paracetamol) use and ADHD diagnosis in children. As such it is still present as first-line treatment, when clinically indicated, used at the lowest effective dose and shortest duration according to regulatory agencies such as EMA.

  • Open Access

    Remote learning and increased screen time during the COVID-19 pandemic as risk factors for Digital Eye Strain: a review

    by Tomasz J. Majszyk, Agnieszka Radziwonka, Bartłomiej Wrochna, Anna Olborska, Ada Niezgoda, Paweł Kosiorek, Gabriela Stondzik, Anna Izabela Garbacz, Jacek Głuski, Agnieszka Brzozowska, et al.

    Digital Eye Strain (DES), also referred to as Computer Vision Syndrome (CVS), is a functional, symptom-based condition associated with prolonged digital display use and characterised by visual fatigue, ocular discomfort or dryness, blurred or fluctuating vision, and headache. During the COVID-19 pandemic, lockdown measures and school closures accelerated the shift towards remote learning, substantially increasing daily screen exposure among children, adolescents, and university students. This narrative review evaluates evidence on the relationship between remote learning, increased screen time during the COVID-19 pandemic, and the risk of Digital Eye Strain. Across pandemic-era studies, prolonged screen-based education was generally associated with a higher prevalence of DES-related symptoms in student populations. However, the available evidence is predominantly observational and relies largely on self-reported screen exposure and subjective symptom measures, with substantial heterogeneity in outcome definitions and assessment tools. Overall, the COVID-19 pandemic appears to have amplified pre-existing screen-related risk factors for Digital Eye Strain rather than introduced a novel ocular condition, while expanding the size of the exposed population. Although causal inference is limited, the consistency of findings across age groups supports the clinical relevance of Digital Eye Strain in remote learning contexts. Future research should prioritise longitudinal designs, clearer differentiation between educational and recreational screen use, and the integration of objective measures of visual behaviour and ocular surface function.


  • Open Access

    Use of mobile applications in the self‑management of gestational diabetes mellitus: a narrative review

    by Anna Izabela Garbacz, Paweł Kosiorek, Agnieszka Radziwonka, Bartłomiej Maciej Wrochna, Anna Olborska, Ada Niezgoda, Gabriela Stondzik, Tomasz Majszyk, Jacek Głuski, Agnieszka Brzozowska, et al.

    INTRODUCTION AND PURPOSE: Gestational diabetes mellitus (GDM) is an increasingly common pregnancy‑related metabolic disorder associated with maternal and perinatal morbidity and an elevated long‑term risk of type 2 diabetes. Effective management relies on structured glucose monitoring, medical nutrition therapy and adequate physical activity, with pharmacotherapy required when lifestyle measures alone do not achieve glycaemic targets. Sustained self‑management is often difficult, particularly when access to specialist care and structured diabetes education is limited. Mobile health technologies offer new options to support daily GDM management. This narrative review summarises recent evidence on smartphone‑based applications for GDM self‑management, focusing on core functions, clinical effectiveness and patient‑reported outcomes, as well as key implementation challenges. BRIEF DESCRIPTION OF THE STATE OF KNOWLEDGE: GDM‑specific applications support glucose logging, graphical feedback, alerts, lifestyle counselling and secure communication with health‑care professionals. These tools appear feasible and acceptable, with high user satisfaction and reports of greater convenience, perceived support and better understanding of GDM. Quantitative data generally indicate non‑inferior glycaemic control compared with conventional care, with some improvements in postprandial glucose and selected maternal and neonatal outcomes, although the evidence base remains limited. SUMMARY (CONCLUSION): Available data support smartphone‑based applications as a promising adjunct to standard GDM care, reinforcing key elements of self‑management and enabling flexible remote surveillance. Further multicentre trials and detailed evaluation of features that sustain engagement and improve clinically meaningful outcomes are required, together with user‑centred design and careful integration of digital decision‑support into antenatal and postpartum diabetes care.

  • Open Access

    Relapsing Polychondritis: Clinical Presentation, Diagnosis and Treatment Approaches

    by Gabriela Stondzik, Anna Izabela Garbacz, Tomasz Julian Majszyk, Jacek Głuski, Agnieszka Brzozowska, Patrycja Borowiecka, Aleksandra WęGlarz, Paweł Kosiorek, Ada Niezgoda, Anna Olborska, et al.

    Background: Relapsing polychondritis (RP) is a rare, chronic inflammatory disease with a relapsing course that leads to damage of cartilage and other proteoglycan‑rich tissues. The variable multisystem presentation and the lack of specific laboratory markers may delay diagnosis, which can result in irreversible deformities and organ‑related complications. Aim: The aim of this paper was to summarise current evidence on the epidemiology, clinical presentation, diagnosis, monitoring, and treatment of RP, with attention to disease heterogeneity and emerging pathogenetic concepts. Materials and methods: This paper was prepared as a narrative literature review. Searches were conducted in PubMed and Scopus, including review articles, observational studies and clinically relevant case series. Results: RP most commonly affects the auricles, nose, and laryngo‑tracheo‑bronchial structures, but may also involve the eyes, inner ear, and cardiovascular system. Diagnosis is primarily clinical, supported by ancillary investigations and exclusion of mimicking conditions; in practice, classification criteria described in the literature are often used. Disease monitoring should include assessment of activity, irreversible damage, and patient functioning; a disease-specific activity index (e.g. RPDAI and RPDAM) may support follow‑up. Treatment is individualised and depends on severity and organ involvement; systemic glucocorticoids are the cornerstone, conventional immunosuppressants are used as steroid‑sparing therapy, and biologic therapies are considered in refractory cases. Conclusions: RP remains a major diagnostic and therapeutic challenge due to its rarity, heterogeneous phenotype, and limited availability of high‑quality clinical evidence. Early recognition, assessment of dominant organ involvement, regular monitoring, and multidisciplinary care are essential.

  • Open Access

    EVALI: Current Understanding of Its Pathophysiology, Diagnosis, and Management

    by Bartłomiej Maciej Wrochna, Anna Olborska, Agnieszka Brzozowska, Gabriela Stondzik, Ada Niezgoda, Anna Izabela Garbacz, Paweł Kosiorek, Agnieszka Radziwonka, Tomasz Julian Majszyk, Jacek Głuski, et al.

    Background: E-cigarette, or Vaping, product use-Associated Lung Injury (EVALI) emerged in 2019 as a novel clinical syndrome, posing a significant public health challenge linked to the inhalation of aerosols from e-cigarette or vaping products, particularly those containing tetrahydrocannabinol (THC) and vitamin E acetate (VEA). Aim: This narrative review synthesizes the current understanding of EVALI's pathophysiology, diagnostic approach, and management principles, drawing upon evidence published from 2017 to 2024. Material and Methods: We conducted a comprehensive narrative synthesis of literature from 2017–2024, focusing on etiological studies, clinical case series, public health reports, and reviews detailing the mechanisms, clinical presentation, diagnostic criteria, and therapeutic outcomes of EVALI. Results: The pathophysiology involves a complex interplay of direct chemical pneumonitis, surfactant dysfunction, and acute lung injury patterns triggered primarily by VEA. Clinical presentation includes respiratory, gastrointestinal, and constitutional symptoms. Diagnosis relies on a meticulous history of vaping, consistent radiological findings (typically bilateral ground-glass opacities on CT), and exclusion of infection. Management is primarily supportive, with systemic glucocorticoids showing efficacy in reducing inflammation and improving outcomes in moderate to severe cases. Conclusions: EVALI represents a severe form of inhalational lung injury directly attributable to toxic substances like VEA in vaping aerosols. While the peak incidence has subsided, it underscores the ongoing risks of unregulated vaping products and highlights critical gaps regarding long-term sequelae. Continued surveillance, public health education, and further research are imperative.

  • Open Access

    Lifestyle modification and selected pharmacological therapies in Polycystic Ovary Syndrome: current evidence and emerging approaches

    by Agnieszka Brzozowska, Anna Izabela Garbacz, Tomasz Julian Majszyk, Jacek Głuski, Patrycja Anna Borowiecka, Aleksandra WęGlarz, Paweł Kosiorek, Ada Niezgoda, Anna Olborska, Bartłomiej Maciej Wrochna, et al.

    Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, associated with hyperandrogenism, menstrual irregularities, infertility, insulin resistance, and increased cardiometabolic risk. Aim: The aim of this narrative review was to summarize current evidence-based therapies for PCOS management, focusing on lifestyle modification and selected pharmacological options. Materials and Methods: A literature search was conducted in PubMed using the term “Polycystic Ovary Syndrome (PCOS)” combined with the following keywords: “lifestyle”, “physical activity”, “exercise”, “diet”, “pharmacotherapy”, “treatment”, “metformin”, “fertility”, “GLP-1”, “inositol”, and “gut microbiota”. Articles published from 2019 onwards were included. Results: Lifestyle modification remains the first-line approach and may improve metabolic, hormonal, and reproductive outcomes. Pharmacotherapy is used as an adjunct when lifestyle measures are insufficient. Established options include metformin, combined oral contraceptives, antiandrogens in selected cases, and ovulation induction agents. Emerging evidence supports GLP-1 receptor agonists for obesity-related PCOS, although long-term data are limited. Inositol and gut microbiota-targeted strategies remain experimental. Conclusions: PCOS management should be individualized and long-term, combining lifestyle interventions with appropriate pharmacotherapy and patient education to improve adherence and outcomes.


  • Open Access

    Menopause and exercise: hormonal influences on cardiovascular regulation: a narrative review

    by Jacek Głuski, Patrycja Anna Borowiecka, Agnieszka Brzozowska, Agnieszka Radziwonka, Anna Izabela Garbacz, Tomasz Julian Majszyk, Aleksandra Karolina WęGlarz, Paweł Kosiorek, Ada Niezgoda, Anna Olborska, et al.

    The menopausal transition is associated with hormonal changes that adversely affect cardiovascular regulation and contribute to increased cardiovascular disease risk in women. Declining estrogen availability is linked to alterations in vascular function, blood pressure regulation, autonomic balance, and metabolic health that extend beyond the effects of chronological aging alone. This narrative review summarizes current evidence on menopause-related cardiovascular changes and examines the effects of physical activity and structured exercise training on vascular, hemodynamic, autonomic, and cardiorespiratory outcomes in peri- and postmenopausal women. Available evidence indicates that menopause is associated with increased arterial stiffness, altered blood pressure regulation, and a shift toward sympathetic predominance. Exercise training, particularly aerobic exercise, is consistently associated with improvements in arterial function, blood pressure control, cardiorespiratory fitness, and autonomic regulation. Resistance-based training shows more variable cardiovascular effects but supports broader functional and metabolic adaptations. Notably, many exercise-related benefits occur independently of significant weight loss, underscoring the importance of physiological rather than purely anthropometric mechanisms. Overall, regular exercise emerges as an effective systems-level strategy for attenuating menopause-related cardiovascular dysregulation and supporting cardiovascular health during and after the menopausal transition.

  • Open Access

    The COVID-19 Pandemic and its Influence on Sleep Quality: A Narrative Review of Prevalence, Correlates, and Implications

    by Agnieszka Radziwonka, Bartłomiej Maciej Wrochna, Anna Olborska, Ada Niezgoda, Paweł Kosiorek, Gabriela Stondzik, Anna Izabela Garbacz, Tomasz Julian Majszyk, Jacek Głuski, Agnieszka Brzozowska, et al.

    Introduction:The COVID-19 pandemic, has been a global stressor, disrupting daily routines and increasing psychological distress. A growing body of evidence indicates a rise in reports of sleep disorders among the population during this pandemic [1]. This narrative review synthesizes current literature to summarize the scale, risk factors, and health implications of pandemic-related sleep disturbances. Aim of the study:This article aims to analyze the prevalence and clinical impact of sleep disturbances during the COVID-19 pandemic, with particular focus on risk groups, contributing psychosocial factors, and associations with mental health. State of Knowledge:Meta-analyses confirm a high global prevalence of sleep problems during the pandemic, with pooled rates of sleep disturbances exceeding 30% in the general population [2]. These problems were significantly more pronounced in specific groups, including patient-facing healthcare workers [3], patients infected with Covid-19, and individuals with pre-existing psychiatric conditions [4]. Key contributing factors included pandemic-related stress, fragmentation of habitual daily patterns, and the onset of circadian system instability [5]. A strong relationship has been established between sleep disturbances and worsened mental health, particularly anxiety and depression [6]. Furthermore, sleep problems have emerged as a persistent symptom of Post-Acute Sequelae of SARS-CoV-2 infection (PASC, or Long COVID) [7]. Conclusion:Sleep disturbances represent an important public health crisis precipitated by the COVID-19 pandemic, manifesting as "coronasomnia". This review concludes that systematically addressing sleep health is crucial for post-pandemic sleep disturbances recovery, necessitating targeted public health strategies that integrate standardized screening in vulnerable populations, promotion of sleep hygiene, and the implementation of evidence-based interventions like cognitive-behavioral therapy for insomnia.